SKVY yields 2000000.00% · ABBV yields 3.06%● Live data
📍 SKVY pulled ahead of the other in Year 1
Combined, SKVY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SKVY + ABBV for your $10,000?
Sentry Technology Corp. designs, manufactures, markets, and services closed circuit television (CCTV), library patron self service, and radio frequency identification (RFID) solutions, as well as EAS security systems. It offers SentryVision SmartTrack, a traveling video system that transmit images from a PTZ camera mounted on a carriage that travels along a rail mounted to the ceiling of any facility; VideoRailway, a traveling camera technology; security and information services through inventory management, self-service, and book detection systems to school, public, and academic libraries; and OperationalVideo, a browser based video application to assist retailers with real time management of security, merchandising audits, and employee procedure compliance. The company also offers EAS security systems, including electromagnetic and RF systems for reducing theft in bookstores; and designs, installs, and maintains CCTV systems for retailers, transportation and distribution, and commercial and industrial companies. It serves retailers, transportation and distribution hubs, couriers and public transportation facilities, libraries, and data centers through dealers in North America, Europe, Latin America, the Middle East, Asia, and Africa. The company was founded in 1996 and is based in Ronkonkoma, New York.
Full SKVY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.